Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 19Thoracic 4Genitourinary 4Gastrointestinal 3Breast 3Head & Neck 2Sarcoma 1Other neoplasm 1Lymphoid 1

Conditions

Carcinoma, Hepatocellular 37Colorectal Neoplasms 16Liver Neoplasms 10Biliary Tract Neoplasms 10Cholangiocarcinoma 7Pancreatic Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Unresectable Hepatocellular Carcinoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Non-resectable 1Microsatellite Instability 1

Interventions

pembrolizumab 59Nivolumab 34Cyclophosphamide 21fludarabine 15Paclitaxel 12Ipilimumab 12atezolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Carboplatin 10Docetaxel 9Cisplatin 9Gemcitabine 8Biopsy 8durvalumab 7aldesleukin 7Radiosurgery 7Interleukin-2 7Bevacizumab 7cemiplimab 6Pemetrexed 6fludarabine phosphate 5avelumab 5Radiotherapy 5Drug Therapy 5spartalizumab 4epacadostat 4enzalutamide 4Taxes 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × tremelimumab × Gastrointestinal × Clear all
NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
53 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

AstraZeneca

Phase 2 Completed
37 enrolled 13 charts
DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡